News

TB R&D Weekly Update: TB Vaccine Efficacy Trial Yields Key Insights and Poor Results

The results of the first TB vaccine efficacy trial in over 90 years was released today showing that the vaccine candidate MVA85A when given as a booster did not provide added protection to infants who had already received BCG. The trial adds scientific value to the field and enhances the field’s understanding and ability in conducting large-scale TB vaccine trials.

Aeras and its partners will be hosting a teleconference to discuss the results and implications on February 6 at 8:30 a.m. EST. Click here for meeting invitation.

Lancet Article “Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial”–click here.

Lancet Commentary “A major event for new tuberculosis vaccines”–click here.

Additional Coverage:

First TB Vaccine Efficacy Study in Almost a Century Provides Key Insights: Vaccine Safe but Does Not Confer Protection, Calls for Redoubling Efforts on Global TB Vaccine Portfolio (Aeras)

Tuberculosis vaccine hopes dashed (BBC)

As Tuberculosis Vaccines Flounder, Developing Nations Join To Fight Drug-Resistant Diseases

Additional R&D News:

Tuberculosis Immunotherapy Grant for Immunoxel Honibe Honey Lozenges

New Drug for an Age-Old Disease

Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis [Review article]. (Int J Tuberc Lung Dis, Feb 2013)

Forsyth scientists gain new understanding of latent tuberculosis

The Tres Cantos Open Lab Foundation and Weill Cornell Medical College Join Forces on Tuberculosis Drug Discovery

Diospyrin inactivates a drug target for tuberculosis in new way

Can (MICs) governments make the global R&D system work for all?

More News
11 Aug 2020
The European Commission (EC) has provided conditional marketing authorization for pretomanid, a novel compound developed by TB Alliance, when used in combination with bedaquiline and linezolid as part of a six month, all-oral regimen for the treatment of adults with XDR-TB or treatment-intolerant...
29 Jul 2020
The WGND is announcing a call for applications to become a part of the WGND Core Group (CG). The CG provides leadership and sets the strategic direction for the work of the WGND. Addmitted applicants will begin their term in September 2020. Current CG membership information is available on the WGND...
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...